Bioxytran Q2 net loss turns to $619,929; H1 net loss widens to $2.69 million

• Bioxytran posted a net loss attributable to shareholders of $619,929, swinging from net profit of $35,439 a year earlier.
• Loss per share was $0.01, turning from break-even EPS of $0.00 in the prior-year quarter.
• Research and development expense climbed to $255,479 from $102,500, driven by higher regulatory costs of $210,719.
• General and administrative expense rose to $399,121 from $121,577, reflecting payroll of $262,567 after no payroll last year.
• Cash fell to $177,384 at June 30, 2026 from $509,914 at year-end; management said it expects cash to run out by September 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioxytran Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038327), on August 14, 2026, and is solely responsible for the information contained therein.